Search Results - "Cubitt, Marion F."

Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease by Roberts, Kevin J., Cubitt, Marion F., Carlton, Timothy M., Rodrigues-Duarte, Lurdes, Maggiore, Luana, Chai, Ray, Clare, Simon, Harcourt, Katherine, MacDonald, Thomas T., Ray, Keith P., Vossenkämper, Anna, West, Michael R., Crowe, J. Scott

“…Anti-TNFα and anti-IL-23 antibodies are highly effective therapies for Crohn’s disease or ulcerative colitis in a proportion of patients. V56B2 is a novel…”
Get full text

A Metabolic Regulator Modulates Virulence and Quorum Sensing Signal Production in Pectobacterium atrosepticum by CUBITT, Marion F, HEDLEY, Peter E, WILLIAMSON, Neil R, MORRIS, Jenny A, CAMPBELL, Emma, TOTH, Ian K, SALMOND, George P. C

“…Plant cell wall-degrading enzymes (PCWDE) are key virulence determinants in the pathogenesis of the potato pathogen Pectobacterium atrosepticum. In this study,…”
Get full text

Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease by Crowe, J. Scott, Roberts, Kevin J., Carlton, Timothy M., Maggiore, Luana, Cubitt, Marion F., Clare, Simon, Harcourt, Katherine, Reckless, Jill, MacDonald, Thomas T., Ray, Keith P., Vossenkämper, Anna, West, Michael R.

“…TNFα is an important cytokine in inflammatory bowel disease. V565 is a novel anti-TNFα domain antibody developed for oral administration in IBD patients,…”
Get full text

Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients by Nurbhai, Suhail, Roberts, Kevin J., Carlton, Timothy M., Maggiore, Luana, Cubitt, Marion F., Ray, Keith P., Reckless, Jill, Mohammed, Hafeez, Irving, Peter, MacDonald, Thomas T., Vossenkämper, Anna, West, Michael R., Parkes, Gareth C., Crowe, J. Scott

“…V565 is an engineered TNFα-neutralising single domain antibody formulated into enteric coated mini-tablets to enable release in the intestine after oral…”
Get full text

Oral delivery of the anti-tumor necrosis factor α domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeys by Crowe, J. Scott, Roberts, Kevin J., Carlton, Timothy M., Maggiore, Luana, Cubitt, Marion F., Ray, Keith P., Donnelly, Mary C., Wahlich, John C., Humphreys, Jonathan I., Robinson, Jan R., Whale, Gary A., West, Michael R.

“…Objective: V565 is a novel oral anti-tumor necrosis factor (TNF)-α domain antibody being developed for topical treatment of inflammatory bowel disease (IBD)…”
Get full text

The rsmS (ybaM) mutation causes bypass suppression of the RsmAB post-transcriptional virulence regulation system in enterobacterial phytopathogens by Monson, Rita E., Apagyi, Katinka, Bowden, Steven D., Simpson, Natalie, Williamson, Neil R, Cubitt, Marion F., Harris, Steve, Toth, Ian K., Salmond, George P. C.

“…Plant cell wall degrading enzymes (PCWDEs) are the primary virulence determinants of soft rotting bacteria such as the potato pathogen, Pectobacterium…”
Get full text